Skip to main content

Advertisement

Table 4 Key efficacy outcomes

From: Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

Efficacy outcome Safety population (n = 80) Treatment cohort (n = 41)
Duration of response, months 18.4 (11.9–29.6) 35.1 (25.5–38.2)
Time to progression, months 13.8 (11.2–20.4) 36.9 (23.5–42.1)
Progression-free survival, months 13.8 (11.2–20.4) 36.0 (23.5–40.2)
Overall survival, months NE NE
  1. All values median (95 % CI)
  2. NE not estimable